Collins J M, Riccardi R, Trown P, O'Neill D, Poplack D G
Cancer Drug Deliv. 1985 Fall;2(4):247-53. doi: 10.1089/cdd.1985.2.247.
Interferons are currently undergoing clinical testing in patients with cancer and other diseases. A variety of routes of administration are being utilized, and there is particular interest in delivery of interferon to the central nervous system. A biphasic decline in plasma concentrations was observed in monkeys following an i.v. bolus, with initial half-times of 15 to 33 min and terminal half-times of 1.7 to 4.6 hours. Total body clearance ranged from 24 to 39 ml/sq. m/min and steady-state volume of distribution was similar to extracellular space. CSF exposure was 1% or less than that of plasma. Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%). Levels in the CSF were not detectable for the i.m. route. For intraventricular doses, CSF exposure was 3,000-fold greater than for i.v. doses, despite a 20-fold lower dose.
干扰素目前正在癌症和其他疾病患者中进行临床试验。正在采用多种给药途径,人们尤其关注将干扰素递送至中枢神经系统。静脉推注后,在猴子身上观察到血浆浓度呈双相下降,初始半衰期为15至33分钟,终末半衰期为1.7至4.6小时。全身清除率范围为24至39毫升/平方米/分钟,稳态分布容积与细胞外液相似。脑脊液中的药物暴露量为血浆的1%或更低。肌肉注射产生的峰值浓度较低,水平更为持久,但生物利用度存在很大差异(范围为19%-103%)。肌肉注射途径在脑脊液中无法检测到药物水平。对于脑室内给药剂量,尽管剂量比静脉给药低20倍,但脑脊液中的药物暴露量比静脉给药高3000倍。